PF-Atlas › Clinical Trials › NCT04594707

A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 in Participants With Idiopathic Pulmonary Fibrosis

PRM-151 · Phase 3

Registry ID

NCT04594707

Phase

Phase 3

Status

Terminated

Drug / intervention

PRM-151 (Zinpentraxin Alfa)

Sponsor

Hoffmann-La Roche

Start

2021-08-30

Enrollment

117

Locations

248

About this trial

This study will evaulate the long-term safety, efficacy and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, administered by intravenous (IV) infusion to participants with idiopathic pulmonary fibrosis (IPF).

View NCT04594707 on ClinicalTrials.gov →

Explore related

All PRM-151 trials All IPF trials

Related trials

PRM-151 — NCT02550873

Medical disclaimer. This page summarizes public trial data for NCT04594707 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.